ClinConnect ClinConnect Logo
Search / Trial NCT05177809

RFC1 Natural History Study

Launched by PROF. DR. MATTHIS SYNOFZIK · Dec 14, 2021

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Rfc1 Canvas Natural History Study Biomarker

ClinConnect Summary

The RFC1 Natural History Study is an international research project that aims to better understand a specific type of ataxia, which is a condition that affects coordination and balance. This study will look at how the condition develops over time and identify potential tools, like digital tests and imaging scans, that could help doctors diagnose it and measure how well treatments work in the future. The study is currently recruiting participants, and it welcomes individuals aged 65 and older who have a confirmed genetic diagnosis related to RFC1 repeat expansions. Additionally, healthy volunteers without any neurological or psychiatric conditions can join as control participants.

If you choose to participate, you can expect to undergo various assessments and tests that will help researchers gather important information about the disease. It's essential that participants are able to provide informed consent, meaning they agree to join the study after understanding what it involves. This study is crucial for advancing knowledge about ataxia and could pave the way for better diagnoses and treatments in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • RFC1: genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1
  • Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND
  • Written informed consent AND
  • Participants are willing and able to comply with study procedures
  • Exclusion Criteria:
  • RFC1: Missing informed consent
  • Controls: evidence of neuropathy, neurodegenerative disease, or movement disorder; inability to give informed consent

About Prof. Dr. Matthis Synofzik

Prof. Dr. Matthis Synofzik is a distinguished clinical trial sponsor renowned for his expertise in neurology and neurodegenerative disorders. With a robust background in clinical research and a commitment to advancing therapeutic strategies, he leads innovative studies aimed at improving patient outcomes in complex neurological conditions. His interdisciplinary approach fosters collaboration among researchers, clinicians, and patients, ensuring that clinical trials are not only scientifically rigorous but also ethically sound and patient-centered. Prof. Synofzik's dedication to excellence in research is reflected in his numerous publications and contributions to the field, positioning him as a key figure in the advancement of neurological healthcare.

Locations

Pisa, , Italy

Tübingen, Baden Württemberg, Germany

Melbourne, Victoria, Australia

São Paulo, State Of São Paulo, Brazil

Strasbourg, , France

Bonn, Nordrhein Westfalen, Germany

Lübeck, Schleswig Holstein, Germany

Napoli, , Italy

Auckland, , New Zealand

Istanbul, , Turkey

Tübingen, , Germany

São Paulo, , Brazil

Patients applied

0 patients applied

Trial Officials

Matthis Synofzik, Prof. Dr.

Principal Investigator

University Hospital Tübingen

Andreas Traschütz, Dr. Dr.

Principal Investigator

University Hospital Tübingen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials